[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

StoneX Group Inc. (SNEX) — Form 4 insider filing

Director Dhamu R. Thamodaran was awarded 113 restricted shares of StoneX common stock on 31-Jul-2025 through the company’s Restricted Stock Program at a stated price of $0.00. The award vests in three equal annual installments. Following the grant, the director’s direct beneficial ownership increases to 36,569 shares.

No shares were sold and no derivative securities were involved. The grant represents <0.001 % of StoneX’s outstanding shares, making the change economically immaterial to the market but modestly strengthening board-level equity alignment. Because the shares were granted rather than purchased, the filing is viewed as routine compensation with limited market impact.

Positive

• Director’s ownership increases, marginally enhancing alignment with shareholder interests.
• Three-year vesting encourages long-term board engagement and retention.

Negative

• Immaterial size; the 113-share grant is too small to indicate insider confidence or influence valuation.
• No cash purchase; award is compensation, not an open-market buy, limiting bullish interpretation.

Insights

Financial Analyst

TL;DR: Routine director stock grant; negligible dilution; neutral market impact.

The 113-share award is a standard component of StoneX’s director compensation plan, costing the company de minimis dilution and signaling no incremental insider conviction because no cash was deployed. Post-transaction ownership of 36,569 shares remains a very small stake relative to the 21 million-share float. Investors should view this as housekeeping rather than a trading signal.

Corporate Governance Specialist

TL;DR: Equity grant supports director alignment, but size is immaterial.

Equity-based compensation helps align directors with shareholders, and a three-year vesting schedule promotes board continuity. However, the tiny fraction of total shares means the governance benefit is incremental at best. No red flags or notable positives beyond routine best practices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	18889	621259.00	43472928	08/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	08/04/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd.			18889	08/04/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Ragosa 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/03/2025	18299	527011.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many StoneX (SNEX) shares did the director acquire?

113 restricted shares were awarded on 31-Jul-2025.

What price was paid for the shares?

The restricted shares were granted at $0.00 as part of director compensation.

What is the director’s total ownership after this transaction?

Dhamu R. Thamodaran now beneficially owns 36,569 SNEX shares directly.

When do the restricted shares vest?

The award vests one-third each year over three years from the grant date.

Does the Form 4 signal insider bullishness?

Because it is a routine compensation grant and not an open-market purchase, the market impact is considered neutral.